2026-04-03T11:07:15-05:00 2025-12-31 410746749 CLIFTONLARSONALLEN LLP 420 SOUTH ORANGE AVENUE SUITE 900 ORLANDO FL 32801 990 2025-01-01 593187624 JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC JAEB 8139758690 15310 AMBERLY DRIVE 350 TAMPA FL 33647 ADAM GLASSMAN PRESIDENT 8139758690 2026-04-01 1 TINA HENTON P00630282 4078021200 2026-04-01 2025 2025-03-06 01:10:19Z ADAM GLASSMAN 15310 AMBERLY DRIVE 350 TAMPA FL 33647 60799055 0 X WWW.JAEB.ORG X 1998 FL DESIGN AND CONDUCT WORLD-CLASS CLINICAL TRIALS AND EPIDEMIOLOGIC RESEARCH. 5 4 187 4 0 0 32326515 38117545 18960490 20175896 325075 371962 34593 1520 51646673 58666923 9698833 3000000 0 0 20497067 21378456 0 0 0 29973426 35596281 60169326 59974737 -8522653 -1307814 21082347 25627763 25337257 31195095 -4254910 -5567332 X OUR MISSION IS TO EXPAND SCIENTIFIC KNOWLEDGE AND IMPROVE PUBLIC HEALTH BY DESIGNING AND CONDUCTING WORLD-CLASS CLINICAL TRIALS AND EPIDEMIOLOGIC RESEARCH. 0 0 51825235 3000000 20175896 SEE SCHEDULE O 51825235 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 1 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 119 0 1 187 1 0 0 0 0 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X X ERICA VOGT 8139758690 15310 AMBERLY DRIVE SUITE 350 TAMPA FL 33647 ROY BECK MEDICAL DIRECTOR 40.00 1.00 X 513682 0 123856 DANA BALL DIRECTOR 1.00 1.00 X 0 0 0 NEIL BRESSLER DIRECTOR 1.00 1.00 X 0 0 0 ANNE LINDBLAD DIRECTOR 1.00 1.00 X 0 0 0 SHAN SHIKARPURI DIRECTOR 1.00 1.00 X 0 0 0 ERICA VOGT CHIEF FINANCIAL OFFICER 40.00 1.00 X 269611 0 59018 ADAM GLASSMAN PRESIDENT 40.00 1.00 X 350563 0 81351 JOHN CRAIG DIRECTOR OF RESEARCH 40.00 0.00 X 277464 0 59178 CRAIG KOLLMAN DIRECTOR OF BIOSTATISTICS 40.00 0.00 X 255810 0 61020 PETER CALHOUN BIOSTATISTICIAN IV 40.00 0.00 X 222733 0 52603 ROBIN GAL DIRECTOR OF RESEARCH OPERATIONS 40.00 0.00 X 209486 0 45502 ALLISON AYALA BIOSTATISTICIAN IV 40.00 0.00 X 198799 0 44976 2298148 0 527504 113 0 1 0 COGNIZANT WORLDWIDE LIMITED 280 BISHOPGATE LONDON UK EC2M4AG SOFTWARE DEVELOPMENT 2162530 FEDERAL EXPRESS 3610 HACKS CROSS ROAD MEMPHIS TN 38125 SHIPPING SERVICES 545745 GSD HEALTH RESEARCH INC 1742 SPYGLASS CIRCLE VISTA CA 92081 SOFTWARE SERVICES 355000 PROTELO INC 340 PALLADIO PARKWAY SUITE 520 FOLSOM CA 95630 SOFTWARE DEVELOPMENT 351331 ADVARRA INC 6100 MERRIWEATHER DR SUITE 600 COLUMBIA MD 21044 IRB SERVICES 260295 11 19675580 18441965 38117545 INDUSTRY PROGRAM SERVICE EXCHANGE 541700 20175896 20175896 20175896 322094 322094 2182000 2132132 49868 49868 49868 MISCELLANEOUS INCOME 900099 1520 1520 1520 58666923 20175896 0 373482 3000000 3000000 1255378 463837 791541 16389677 12054576 4335101 726100 572674 153426 1699571 1253484 446087 1307730 934636 373094 5618 5618 88425 88425 3337 3337 966809 902743 64066 4042 4042 25386 25386 1818950 756440 1062510 258586 258586 1052899 981609 71290 169895 169895 167598 167598 SUBCONTRACTOR PAYMENTS 26672138 26672138 RESEARCH EXPENSES 4206447 4206447 DUES & SUBSCRIPTIONS 42434 42434 TRAINING 34150 34150 79567 22609 56958 59974737 51825235 8149502 0 2863735 908198 8968703 4498681 5245794 11872238 1472099 184046 1444340 779950 548582 664390 1067835 2900318 3849157 915599 750735 21082347 25627763 2792914 4362473 21568416 26013278 975927 819344 25337257 31195095 X -4254910 -5567332 -4254910 -5567332 21082347 25627763 -1307814 -4608 0 X 0 1 X 1 1 1 X 24875930 28983474 35083784 32326515 38117545 159387248 24875930 28983474 35083784 32326515 38117545 159387248 7559764 151827484 2389 5171 206410 241673 322094 777737 34595 1036 35631 160200616 72947320 0.94770 0.94080 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 143971 43191 100780 1300369 736759 563610 664390 LEASE LIABILITY 819344 819344 1 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 27 PROGRAM SERVICES CLINICAL RESEARCH SITES CONTRACTED TO ENROLL PATIENTS AND CONDUCT RESEARCH ACTIVITIES 240945 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 26 PROGRAM SERVICES CLINICAL RESEARCH SITES CONTRACTED TO ENROLL PATIENTS AND CONDUCT RESEARCH ACTIVITIES 2816877 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 3 PROGRAM SERVICES CLINICAL RESEARCH SITES CONTRACTED TO ENROLL PATIENTS AND CONDUCT RESEARCH ACTIVITIES 103491 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 2 PROGRAM SERVICES CLINICAL SITES WHERE PATIENTS ARE ENROLLED IN US-COORDINATED CLINICAL TRIALS. 37410 SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, 0 6 PROGRAM SERVICES CLINICAL SITES WHERE PATIENTS ARE ENROLLED IN US-COORDINATED CLINICAL TRIALS. 117947 0 64 0 0 0 64 3316670 0 3316670 0 0 0 0 0 0 PART I, LINE 2: THE ONLY GRANTS OR ASSISTANCE USED OUTSIDE THE US ARE FOR PROGRAM SERVICES (CLINICAL SITES) IN THE CONDUCT OF CLINICAL TRIALS. SUBRECIPIENTS (SITES) OUTSIDE THE US ARE MONITORED USING THE SAME PROCEDURES AS IS REQUIRED FOR SUBRECIPIENTS (SITES) INSIDE THE US. 1 JAEB CENTER RESEARCH TRUST INC 15310 AMBERLY DRIVE TAMPA FL 33647 270717710 501(C)(3) 3000000 0 N/A N/A GENERAL SUPPORT 1 0 PART I, LINE 2: JCHR MADE GRANTS ONLY TO ITS OWN RELATED ORGANIZATION. X X X 0 0 0 0 0 0 0 0 0 ROY BECK MEDICAL DIRECTOR 513682 0 0 0 0 0 31000 0 92856 0 637538 0 0 0 ADAM GLASSMAN PRESIDENT 350563 0 0 0 0 0 33531 0 47820 0 431914 0 0 0 JOHN CRAIG DIRECTOR OF RESEARCH 277464 0 0 0 0 0 46839 0 12339 0 336642 0 0 0 ERICA VOGT CHIEF FINANCIAL OFFICER 269611 0 0 0 0 0 47000 0 12018 0 328629 0 0 0 CRAIG KOLLMAN DIRECTOR OF BIOSTATISTICS 255810 0 0 0 0 0 18970 0 42050 0 316830 0 0 0 PETER CALHOUN BIOSTATISTICIAN IV 222733 0 0 0 0 0 33500 0 19103 0 275336 0 0 0 ROBIN GAL DIRECTOR OF RESEARCH OPERATIONS 209486 0 0 0 0 0 31000 0 14502 0 254988 0 0 0 ALLISON AYALA BIOSTATISTICIAN IV 198799 0 0 0 0 0 23500 0 21476 0 243775 0 0 0 PART I, LINE 3 THE BOARD OF DIRECTORS SHALL ANNUALLY REVIEW AND APPROVE THE COMPENSATION OF THE CORPORATE OFFICERS, ANY KEY EMPLOYEES (AS DEFINED BY THE IRS), AND THE NEXT FIVE HIGHEST COMPENSATED EMPLOYEES AS LISTED ON THE ORGANIZATION'S PRIOR YEAR FORM 990. IT IS THE BOARD'S INTENTION THAT THIS POLICY AND ITS ASSOCIATED PROCEDURES WILL MEET THE REBUTTABLE PRESUMPTION TEST UNDER IRC 4958 AND TREASURY REGULATION 53.4958-6. THE PURPOSE OF THE ANNUAL REVIEW IS TO ENSURE THAT THE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE BOARD WILL KEEP ROBUST MINUTES OF ITS DELIBERATIONS AND DECISIONS, THE PRESIDENT'S REPORTS, THE CORPORATE TREASURER'S REPORTS, AND ANY OTHER SUPPORTING DOCUMENTATION THAT IT RELIES ON FOR ITS COMPENSATION DECISIONS. ALL THESE DOCUMENTS WILL BE DELIVERED TO THE CORPORATE SECRETARY PROMPTLY AFTER THE BOARD MEETING FOR ENTRY INTO THE CORPORATE BOOKS AND RECORDS. PART III, LINE 4A DURING 2025, JCHR WAS ENGAGED IN 61 CLINICAL STUDIES, WHICH CULMINATED IN 53 SCIENTIFIC PUBLICATIONS AND 58 PRESENTATIONS AT PROMINENT NATIONAL AND INTERNATIONAL CONFERENCES. IN 2025, JCHR RECEIVED GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (6), HELMSLEY CHARITABLE TRUST (7), BREAKTHROUGH T1D (5), FOUNDATION FIGHTING BLINDNESS (6), CYSTIC FIBROSIS FOUNDATION (4), FOOD AND DRUG ADMINISTRATION (1), AND NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH (1). COLLABORATIONS WITH INDUSTRY CONTINUE TO BE AN INTEGRAL PART OF OUR WORK. JCHR WAS ENGAGED IN COLLABORATIONS WITH 14 INDUSTRY PARTNERS SPANNING 21 STUDIES, INCLUDING 11 INVESTIGATOR INITIATED STUDIES. SEVERAL STUDIES ARE FUNDED BY MULTIPLE SOURCES. FOR EXAMPLE, ONE CLINICAL TRIAL EVALUATING FENOFIBRATE FOR DIABETIC RETINOPATHY IS A LARGE COLLABORATION WITH FUNDS PROVIDED BY THE NATIONAL INSTITUTES OF HEALTH (NATIONAL EYE INSTITUTE AND NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASE), BREAKTHROUGH T1D, HELMSLEY CHARITABLE TRUST, AND ROCHE. JCHR ALSO SELF-FUNDED ONE STUDY AND NUMEROUS STATISTICAL ANALYSIS PROJECTS USING DATASETS FROM PREVIOUSLY COMPLETED STUDIES. AMONG APPROXIMATELY 2,705 ENTITIES RECEIVING NIH FUNDING IN 2025, JCHR RANKS IN THE TOP 8 PERCENT. OUT OF APPROXIMATELY 59,500 NIH GRANTS AWARDED IN 2025, JCHR HAD THE 108TH- (TOP 0.18 PERCENT) AND 202ND - (TOP 0.34 PERCENT) LARGEST GRANTS (SOURCE: BLUE RIDGE INSTITUTE FOR MEDICAL RESEARCH, 2025). DURING 2025, JCHR'S RESEARCH EFFORTS FOCUSED ON THREE MAIN THERAPEUTIC AREAS: DIABETES RESEARCH: A MULTITUDE OF CLINICAL TRIALS AND OBSERVATIONAL STUDIES INVOLVED RESEARCH IN TYPE 1, TYPE 2, AND GESTATIONAL DIABETES, ENCOMPASSING PEDIATRIC AND ADULT POPULATIONS INCLUDING MATERNAL-FETAL HEALTH OUTCOMES. MANY STUDIES FOCUSED ON ADVANCING TECHNOLOGY-DRIVEN DIABETES MANAGEMENT WITH ARTIFICIAL PANCREAS SYSTEMS, INSULIN PUMPS, AND CONTINUOUS GLUCOSE MONITORS (CGMS), WHILE OTHERS INVOLVED THE ASSESSMENT OF GROWING ADJUNCT THERAPY USE IN DIABETES CARE AS WELL AS INTERVENTIONAL STRATEGIES TO PRESERVE ENDOGENOUS INSULIN PRODUCTION, UTILIZE INHALED INSULIN, OR LEVERAGE ENHANCED PATIENT AND CAREGIVER EDUCATION INCLUDING AROUND EXERCISE REGIMENS TO IMPROVE GLUCOSE CONTROL. EYE DISEASE RESEARCH: JCHR CONTINUED ITS ROLE AS A COORDINATING CENTER FOR THREE MAJOR NETWORKS AS WELL AS INDIVIDUAL EYE DISEASE STUDIES: 1. THE DRCR RETINA NETWORK, INVESTIGATING DIABETIC RETINOPATHY, AGE-RELATED MACULAR DEGENERATION, AND OTHER RETINAL DISEASES. 2. THE PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG), FOCUSING ON A WIDE RANGE OF CHILDHOOD EYE CONDITIONS. 3. THE FOUNDATION FIGHTING BLINDNESS CONSORTIUM, DEDICATED TO STUDYING RARE RETINAL DISEASES. ADDITIONALLY, JCHR IS CURRENTLY COORDINATING A STUDY ON LONG-TERM OUTCOMES FOLLOWING CORNEAL TRANSPLANTATION. CYSTIC FIBROSIS RESEARCH: JCHR'S GROWING RESEARCH PORTFOLIO INCLUDES A TRIAL INVESTIGATING USE OF THE BIONIC PANCREAS SYSTEM TO MANAGE CYSTIC FIBROSIS-RELATED DIABETES AS WELL AS OBSERVATIONAL STUDIES SEEKING TO BETTER CHARACTERIZE OTHER PHYSIOLOGICAL AND METABOLIC COMPLICATIONS OF CYSTIC FIBROSIS. KEY STUDIES EXAMINED THE IMPACT OF NUTRITION, MUSCLE STRENGTH, AND GLUCOSE MONITORING TECHNOLOGIES ON LUNG FUNCTION AND OVERALL HEALTH OUTCOMES IN INDIVIDUALS WITH CYSTIC FIBROSIS. FORM 990, PART VI, SECTION B, LINE 11B A COMPLETE COPY OF FORM 990 INCLUDING ALL SUPPORTING SCHEDULES WILL BE PROVIDED TO THE BOARD OF DIRECTORS AT ITS ANNUAL MEETING FOR REVIEW AND ACCEPTANCE PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ANY BOARD DIRECTOR, CORPORATE OFFICER, OR MEMBER OF A BOARD COMMITTEE WHO HAS DIRECT OR INDIRECT FINANCIAL INTEREST, AS DEFINED BELOW, IS AN INTERESTED PERSON. IF A PERSON IS AN INTERESTED PERSON WITH RESPECT TO ANY AFFILIATE OR SUBSIDIARY OF THE CORPORATION, HE/SHE IS AN INTERESTED PERSON WITH RESPECT TO THE CORPORATION AND ALL AFFILIATED OR SUBSIDIARY ENTITIES. A CONFLICT OF INTEREST SHALL BE DEEMED TO EXIST AT ANY TIME WHEN AN INTEREST HELD, INCLUDING WITHOUT LIMITATION A FINANCIAL INTEREST, OR RELATIONSHIP MAINTAINED BY AN INTERESTED PERSON, PROHIBITS OR INHIBITS, OR POTENTIALLY PROHIBITS OR INHIBITS, THE INTERESTED PERSON FROM EXERCISING INDEPENDENT JUDGMENT IN THE BEST INTERESTS OF THE CORPORATION. A CONFLICT OF INTEREST SHALL NOT EXIST IF RESULTING SOLELY FROM THE NORMAL CONDUCT OF ACTIVITIES AND BUSINESS BY AND BETWEEN THE CORPORATION OR OTHER AFFILIATES OF THE CORPORATION. AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF THE FACTS AND CIRCUMSTANCES OF ANY CONFLICT OF INTEREST OR CONFLICT OF LOYALTY TO THE APPROPRIATE GOVERNANCE BODY WITH RESPECT TO ANY ACTION OR PROPOSED ACTION THAT GIVES RISE TO A CONFLICT OF INTEREST OR CONFLICT OF LOYALTY. DISCLOSURE MUST BE MADE TO THE BOARD OF DIRECTORS OR THE BOARD OF DIRECTORS COMMITTEE AS APPROPRIATE TO THE CIRCUMSTANCES. AFTER DISCLOSURE OF THE CONFLICT OF INTEREST OR CONFLICT OF LOYALTY AND ALL MATERIAL FACTS RELATED THERETO, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE ANY BOARD OF DIRECTORS OR COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD DIRECTORS OR COMMITTEE MEMBERS SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. IN THE CASE OF A DISCLOSURE TO A COMMITTEE, THE COMMITTEE MAY REFER THE MATTER FOR DECISION TO THE BOARD OF DIRECTORS. PENDING REVIEW AND RESOLUTION BY THE BOARD OF DIRECTORS OR BOARD COMMITTEE, THE INTERESTED PERSON SHALL LEAVE DURING ANY DELIBERATIONS OR ACTION CONCERNING THE MATTER THAT GIVES RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS SHALL ANNUALLY REVIEW AND APPROVE THE COMPENSATION OF THE CORPORATE OFFICERS, ANY KEY EMPLOYEES (AS DEFINED BY THE IRS), AND THE NEXT FIVE HIGHEST COMPENSATED EMPLOYEES AS LISTED ON THE ORGANIZATION'S PRIOR YEAR FORM 990. IT IS THE BOARD'S INTENTION THAT THIS POLICY AND ITS ASSOCIATED PROCEDURES WILL MEET THE REBUTTABLE PRESUMPTION TEST UNDER IRC 4958 AND TREASURY REGULATION 53.4958-6. THE PURPOSE OF THE ANNUAL REVIEW IS TO ENSURE THAT THE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE BOARD WILL KEEP ROBUST MINUTES OF ITS DELIBERATIONS AND DECISIONS, THE PRESIDENT'S REPORTS, THE CORPORATE TREASURER'S REPORTS, AND ANY OTHER SUPPORTING DOCUMENTATION THAT IT RELIES ON FOR ITS COMPENSATION DECISIONS. ALL THESE DOCUMENTS WILL BE DELIVERED TO THE CORPORATE SECRETARY PROMPTLY AFTER THE BOARD MEETING FOR ENTRY INTO THE CORPORATE BOOKS AND RECORDS. THE PROCESS DESCRIBED HERE WAS LAST COMPLETED IN 2025. FORM 990, PART VI, SECTION C, LINE 19 THE AUDITED FINANCIAL STATEMENTS, FORM 990S, AND FORM 1023 ARE MADE AVAILABLE TO THE PUBLIC ON THE ORGANIZATION'S WEBSITE AND UPON REQUEST. JAEB CENTER RESEARCH TRUST INC 15310 AMBERLY DRIVE TAMPA FL 33647 270717710 SUPPORT FL 501(C)(3) LINE 12B, II N/A 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 JAEB CENTER RESEARCH TRUST INC B 3000000 CASH